Moxifloxacin 400mg tablets
Requires a prescription from a doctor or prescriber
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Moxifloxacin
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Moxifloxacin
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Moxifloxacin
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
16 branded products available
MHRA licensed products
View all licensed products for Moxifloxacin on the MHRA register
Avelox 400mg tablets
Moxifloxacin 400mg tablets
Moxifloxacin 400mg tablets
Moxifloxacin 400mg tablets
Moxifloxacin 400mg tablets
Moxifloxacin 400mg tablets
Moxifloxacin 400mg tablets
Moxifloxacin 400mg tablets
Moxifloxacin 400mg tablets
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
WHO defined daily dose (DDD)
400 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(3)
Antimicrobial prescribing: delafloxacin for community-acquired pneumonia (ES37)
Cellulitis and erysipelas: antimicrobial prescribing (NG141)
Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing (NG114)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 10 · Randomised trials: 23 · 1999–2026
Showing the 50 most relevant studies, sorted by most relevant.
R. Bowen, A. Zhou, Sailaja Bondalapati, et al.
The British journal of ophthalmology, 2018
A. Diacon, R. Dawson, F. von Groote-Bidlingmaier, et al.
Lancet, 2012
R. Ruslami, A. Ganiem, S. Dian, et al.
The Lancet. Infectious diseases, 2013
F. Brunkhorst, M. Oppert, G. Marx, et al.
JAMA, 2012
R. Dawson, A. Diacon, D. Everitt, et al.
Lancet, 2015
Yang Li, W. Le, Sai Li, et al.
International Journal of STD & AIDS, 2017
Li Q, Wang L, Xu H, et al.
2026
- Lung Neoplasms
- Stevens-Johnson Syndrome
- Anti-Bacterial Agents
E. Alexander, L. Goldberg, Anita F. Das, et al.
JAMA, 2019
C. Barrera, A. Mykietiuk, H. Metev, et al.
The Lancet. Infectious diseases, 2016
Wendy Carr, E. Kurbatova, Angela M. Starks, et al.
MMWR. Morbidity and mortality weekly report, 2022
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
1 found
Half-life
11.5-15.6 hours
Mechanism
The bactericidal action of moxifloxacin results from inhibition of the enzymes t…
Food interactions
2 warnings
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
90%
Half-life
11.5-15.6 hours
Protein binding
50%
Volume of distribution
1.7 to 2.7 L/kg
Metabolism
52%
Elimination
45%
Clearance
2 L/h
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 945 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
PMID:17567603 PMID:18790802 PMID:22013166 PMID:22323612
May play a role in regulating the period length of BMAL1 transcriptional oscillation (By similarity)
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC S01AE07
ATC J01MA14
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Moxifloxacin
Additional database identifiers
Drugs Product Database (DPD)
12034
ChemSpider
134802
BindingDB
50366824
PDB
MFX
ZINC
ZINC000003826253
GenBank Gene Database
L42023
GenBank Protein Database
1574722
UniProt Accession
GYRA_HAEIN
GenBank Gene Database
L42023
GenBank Protein Database
1574370
UniProt Accession
PARC_HAEIN
GenBank Gene Database
X71437
UniProt Accession
GYRB_STAAU
UniProt Accession
GYRA_STAAU
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11989
GenAtlas
TOP2A
GeneCards
TOP2A
GenBank Gene Database
J04088
GenBank Protein Database
292830
Guide to Pharmacology
2637
UniProt Accession
TOP2A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9204
GenAtlas
PON1
GeneCards
PON1
GenBank Gene Database
M63012
GenBank Protein Database
190192
UniProt Accession
PON1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2596
GenAtlas
CYP1A2
GeneCards
CYP1A2
GenBank Gene Database
Z00036
Guide to Pharmacology
1319
UniProt Accession
CP1A2_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72